Pharmacokinetic interaction between indinavir and darunavir with low-dose ritonavir in healthy volunteers

Intervirology

Volumn 53, Issue 3, 2010, Pages 176-182

  Sekar, Vanitha ^a   Lefebvre, Eric ^a   De Marez, Tine ^a   De Pauw, Martine ^b   De Paepe, Els ^b   Vangeneugden, Tony ^b   Hoetelmans, Richard M W ^b  

^a Tibotec Inc   (United States)

^b TIBOTEC BVBA   (Belgium)

Author keywords

Darunavir; Indinavir; Pharmacokinetic interactions; Ritonavir

Indexed keywords

ATAZANAVIR; DARUNAVIR; INDINAVIR; RITONAVIR;

ADULT; ARTICLE; BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; HYPERBILIRUBINEMIA; HYPERCHOLESTEROLEMIA; LOW DRUG DOSE; MACULOPAPULAR RASH; MALE; MORNING DOSAGE; NEPHROLITHIASIS; NEUROLOGIC DISEASE; NORMAL HUMAN; PRIORITY JOURNAL; SKIN DISEASE; STEADY STATE; SUBCUTANEOUS TISSUE;

ADULT; ANTI-HIV AGENTS; DRUG INTERACTIONS; FEMALE; HUMAN EXPERIMENTATION; HUMANS; INDINAVIR; MALE; PLASMA; RITONAVIR; SULFONAMIDES; YOUNG ADULT;

EID: 77449140680     PISSN: 03005526     EISSN: None     Source Type: Journal    
DOI: 10.1159/000289341     Document Type: Article

References (25)

1. PREZISTA TM (darunavir) Summary of Product Characteristics, 2009, Tibotec Inc. http:// www.emea.europa.eu/humandocs/PDFs/ EPAR/prezista/emea-combined- h707en.pdf (accessed 19 November 2009).
2. PREZISTA TM (darunavir) US Prescribing Information; revised June 2009. Tibotec Inc. http://www.prezista.com/prezista/documents/ us-package-insert.pdf. (accessed 19 November 2009).
3. De Meyer S, Azijn H, Surleraux D, et al: TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother 2005; 49: 2314-2321. (Pubitemid 40734460)
4. Sekar V, Guzman S, Stevens T, et al: Absolute bioavailability of TMC114 administered in the absence and presence of low-dose ritonavir. 7th International Workshop on Clinical Pharmacology of HIV Therapy, Lisbon, 2006, abstr 86.
5. Crixivanα(indinavir) Summary of Product Characteristics, revised 7 October 2006. Merck Sharp & Dohme Ltd. http://www. emea.europa.eu/humandocs/ PDFs/EPAR/ Crixivan/H-128-PI-en.pdf (accessed 29 April 2008).
6. Saah AJ, Winchell GA, Nessly ML, et al: Pharmacokinetic profile and tolerability of indinavir-ritonavir combinations in healthy volunteers. Antimicrob Agents Chemother 2001; 45: 2710-2715. (Pubitemid 32906661)
7. Panel on Antiretroviral Guidelines for Adults and Adolescents: Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services, 2008, pp 1-139. http://www.aidsinfo. nih.gov/ContentFiles/ AdultandAdolescentGL.pdf (accessed 19 November 2009).
8. Boffito M, Moyle GJ: Pharmacokinetic considerations for combining 2 protease inhibitors. AIDS Read 2004; 14: 110-112, 115-116. (Pubitemid 38339411)
9. Norvirα(ritonavir) Summary of Product Characteristics; revised 27 August 2006, Abbott Laboratories L., UK. http://www.emea. europa.eu/humandocs/ PDFs/EPAR/Norvir/ H-127-PI-en.pdf (accessed 29 April 2008).
10. Sekar V, Spinosa-Guzman S, Meyvisch P, et al: Cocktail study to investigate the in-vivo drug interaction potential of darunavir coadministered with low-dose ritonavir (DRV/ r; RTV) on cytochrome P450 enzymes 2D6, 2C9 and 2C19. 9th International Workshop on Clinical Pharmacology of HIV Therapy (IWCPHIV), New Orleans, 2008, abstr P23.
11. Bouche MP, Michielsen L, Piot M, et al: Swift and simultaneous determination of darunavir (TMC114) and ritonavir in human plasma using LC-MS/MS. 17th Int Mass Spectrom Conf (IMSC), Prague, 2006, abstr TuP-042.
12. Data on File. Tibotec Inc.
13. Koch G: The use of nonparametric methods in the statistical analysis of the two-period change-over design. Biometrics 1972; 28: 577-584.
14. Bulgheroni E, Citterio P, Croce F, et al: Analysis of protease inhibitor combinations in vitro: activity of lopinavir, amprenavir and tipranavir against HIV type 1 wild-type and drug-resistant isolates. J Antimicrob Chemother 2004; 53: 464-468. (Pubitemid 38380244)
15. Boffito M, Maitland D, Samarasinghe Y, et al: The pharmacokinetics of HIV protease inhibitor combinations. Curr Opin Infect Disease 2005; 18: 1-7. (Pubitemid 41716233)
16. Walmsley S, Leith J, Katlama C, et al: Pharmacokinetics and safety of tipranavir/ritonavir (TPV/r) alone or in combination with saquinavir (SQV), amprenavir (APV), or lopinavir (LPV): interim analysis of BI1182.51. 15th International AIDS Conference, Bangkok, 2004, abstr WeOrB1236.
17. Kashuba AD, Tierney C, Downey GF, et al: Combining fosamprenavir with lopinavir/ ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results. AIDS 2005; 19: 145-152. (Pubitemid 40409533)
18. Stephan C, Hentig N, Kourbeti I, et al: Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir. AIDS 2004; 18: 503-508. (Pubitemid 38365878)
19. Ribera E, Lopez RM, Diaz M, et al: Steadystate pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother 2004; 48: 4256-4262. (Pubitemid 39434884)
20. Boffito M, Maitland D, Dickinson L, et al: Pharmacokinetics of saquinavir hard gel (SQV)/ritonavir and atazanavir when combined once daily in HIV type 1-infected individuals administered different atazanavir doses. AIDS Res Hum Retrovir 2006; 22: 749-756. (Pubitemid 44735001)
21. Boffito M, Kurowski M, Kruse G, et al: Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen. AIDS 2004; 18: 1291-1297. (Pubitemid 38822707)
22. Chiba M, Hensleigh M, Nishime JA, Balani SK, Lin JH: Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor. Drug Metab Dispos 1996; 24: 307-314. (Pubitemid 26087084)
23. Profit L, Eagling V, Back D: Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors. AIDS 1999; 13: 1623-1627. (Pubitemid 30015708)
24. Jiménez-Nácher I, García B, Barreiro P, et al: Trends in the prescription of antiretroviral drugs and impact on plasma HIV-RNA measurements. J Antimicrob Chemother 2008; 62: 816-822
25. Sekar V, de Meyer S, Vangeneugden T, et al: Pharmacokinetic/ pharmacodynamic (PK/ PD) analyses of TMC114 in the POWER 1 and POWER 2 trials in treatment-experienced HIV-infected patients. Conference on Retroviruses and Opportunistic Infections (CROI), Denver, 2006, abstr J-121.